Depomed and Esprit Announce Availability of ProQuin(R)XR 3-Tablet Blister Packs.

MENLO PARK, Calif. & EAST BRUNSWICK, N.J. -- Depomed, Inc. (NASDAQ:DEPO) and Esprit Pharma, Inc. announced today that Once-Daily ProQuin(R)XR, the new, prolonged release once-daily formulation of ciprofloxacin hydrochloride for the treatment of uncomplicated urinary tract infections (uUTI), is now available in 3-tablet blister packs, in addition to the original launch packaging of a bottle of 50 tablets. Esprit's 190-person sales and managed care organization are actively calling on physician offices and retail pharmacies nationwide.

"We are pleased to be able to offer physicians and pharmacies packaging options that will address the type and volume of prescriptions they are managing," said John Spitznagel, chairman and chief executive officer of Esprit. "For the high volume ProQuin XR users, the 50-count bottle remains available. The recent launch of the 3-tablet blister pack will provide a convenient alternative for patients when physicians prescribe three tablets, one per day, for the treatment of uUTI infections."

John W. Fara, Ph.D., chairman, president and chief executive officer of Depomed, added, "I am pleased from a manufacturing perspective that we were able to respond quickly to the request from the marketplace for variations in ProQuin XR packaging. We believe the new ProQuin XR 3-tablet blister pack will help Esprit further penetrate the urology, women's health and key primary care physician markets."

In July 2005, Depomed and Esprit entered into a commercialization agreement for ProQuin XR. Esprit launched ProQuin XR in the U.S. urology market in the fourth quarter 2005, and has subsequently launched the product into other attractive physician markets including women's health and key primary care markets. Depomed retains manufacturing rights and Esprit is responsible for sales, marketing and distribution.

About ProQuin(R) XR

ProQuin(R)XR is a once-daily prolonged-release formulation of ciprofloxacin hydrochloride approved to treat uncomplicated urinary tract infections (UTIs). UTIs are bacterial infections frequently caused by E. coli and are typically treated with antibiotics. Patients should not take ProQuin(R)XR if they are allergic to, or have ever had a severe reaction to, ciprofloxacin or to any other "quinolone" antibiotics. ProQuin(R)XR is generally well tolerated. The most common side effects with ProQuin(R)XR include vaginal yeast infection and headache. ProQuin XR is available in 50-count bottles (NDC: 13913-001-50) and 3-count blister packs (NDC: 15456-001-03). Pharmacy ordering information is available by emailing [e-mail]. To order product direct, please call [phone]. For more info please visit www.proquinxr.com.

About Esprit

Esprit Pharma is a niche oriented pharmaceutical company focused on specialty therapeutics to improve patient outcomes in the urology therapeutic area. Led by a strong and experienced management team, the Company focuses on exploring and identifying opportunities to selectively acquire and enhance the market potential of novel, commercially available therapeutics and late-stage development drugs addressing the needs of its market space. A privately held Company, Esprit Pharma has investment support from the leading healthcare venture capital and private equity firms of Domain Associates, LLC (http://www.domainvc.com/), New Enterprise Associates (http://www.nea.com/), and Apax Partners, Inc. (http://www.apax.com/).

About Depomed

Depomed, Inc. is a specialty pharmaceutical company utilizing its innovative AcuForm(TM) drug delivery technology to develop novel oral products and improved, extended release formulations of existing oral drugs. AcuForm-based products are designed to provide once daily administration and reduced side effects, improving patient convenience, compliance and pharmacokinetic profiles. ProQuin(R) XR (ciprofloxacin hydrochloride) once daily, extended-release tablets have been approved by the FDA for the treatment of uncomplicated urinary tract infections. In addition, regulatory applications for once daily Glumetza(TM) for the treatment of Type II diabetes have been approved in the U.S. and Canada. The company completed a Phase II trial in postherpetic neuralgia with its product, Gabapentin GR. Additional information about Depomed may be found at its web site, www.depomedinc.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995. The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties including, but not limited to those related to our commercialization efforts and those of our collaborative partners, our research and development efforts, including pre-clinical and clinical testing; regulation by the FDA and other government agencies; the timing of regulatory applications and product launches; and other risks detailed in the company's Securities and Exchange Commission filings, including the company's Annual Report on Form 10-K. You are cautioned not to place undue reliance on these forward-looking statements which speak only as of the date hereof. The company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.